Another arthritis medicine! WHO prequalified for the treatment of coronavirus … Significantly reduces the risk

Another arthritis medicine WHO prequalified for the treatment of coronavirus

In the written statement made by WHO, it was shared that Tocilizumab, which has been given intravenously to severe Kovid-19 patients, has significantly reduced the risk of death. In this context, it was noted that Kovid-19 treatment with Tocilizumab is the 7th treatment method that passed the prequalification of WHO.

PRICE OF A SINGLE DOSE 500-600 DOLLARS

It has been reported that for now, the drug will only be recommended for severe and critical patients and will be administered in clinical settings with standard Kovid-19 treatment equipment, under the supervision of healthcare professionals.

It was stated that a single dose of Tocilizumab is 500-600 dollars, but if more than one manufacturer enters the global market, its price may decrease.

IT HAS BEEN TRIED FOR A TIME

Tocilizumab, which is used in the treatment of rheumatoid arthritis in around 120 countries around the world, has been tested on severe patients for the treatment of Kovid-19 in some countries for a while.

The World Health Organization last recommended the use of rheumatoid arthritis drugs Baricitinib and Interleukin-6 in the treatment of Kovid-19 on January 14. (AA)

mn-1-general